References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. doi:10.1182/blood-2016-03-643544
Reboursiere E, Chantepie S, Gac AC, Reman O (2015) Rare but authentic Philadelphia-positive acute myeloblastic leukemia: two case reports and a literature review of characteristics, treatment and outcome. Hematol Oncol Stem Cell Ther 8(1):28–33
Neuendorff NR, Burmeister T, Dörken B, Westermann J (2016) BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Ann Hematol 95(8):1211–1221. doi:10.1007/s00277-016-2721-z
Nacheva EP, Grace CD, Brazma D, Gancheva K, Howard-Reeves J, Rai L, Gale RE, Linch DC, Hills RK, Russell N, Burnett AK, Kottaridis PD (2013) Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol 161(4):541–550. doi:10.1111/bjh.12301
Grimwade D, Ivey A, Huntly BJ (2016) Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 127(1):29–41. doi:10.1182/blood-2015-07-604496
Schnittger S, Haferlach C, Nadarajah N, Meggendorfer M, Fasan A, Rose D, Alpermann T, Kern W, Haferlach T (2014) CML Patients with Resistance to Tyrosine Kinase Inhibitors and without BCR-ABL1 Resistance Mutation Frequently Carry Other Gene Mutations. Blood 124:4516
Paschka P, Schlenk RF, Gaidzik VI et al (2015) ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica 100(3):324–330. doi:10.3324/haematol.2014.114157
Neuendorff NR, Schwarz M, Hemmati P, Türkmen S, Bommer C, Burmeister T, Dörken B, le Coutre P, Arnold R, Westermann J (2015) BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(−) subclone as a cause of refractory disease with nilotinib treatment. Acta Haematol 133(2):237–241. doi:10.1159/000368176
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s00277-016-2879-4.
Rights and permissions
About this article
Cite this article
Maël, H., Audrey, B., Evelyne, CB. et al. BCR-ABL-positive acute myeloid leukemia: About one case treated with ponatinib. Ann Hematol 96, 335–336 (2017). https://doi.org/10.1007/s00277-016-2855-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2855-z